Table 1.

Binding of humanized or chimeric mAbs on B-cell lines



Geometric mean fluorescence

None
Anti-CEA: hMN14
Anti-CD74: hLL1
Anti-CD22: hLL2
Anti-CD20: hA20
Anti-CD20: rituximab
Anti-HLA-DR: hL243γ4P
Daudi   3.2   3.2   48.8   51.7   241.0   380.5   937.4  
Namalwa   2.6   2.4   7.8   6.4   10.1   14.1   260.9  
Raji   6.9   7.0   95.1   22.6   267.1   394.6   972.0  
Ramos   3.1   3.1   23.3   14.6   203.7   375.0   277.6  
RL   2.4   2.8   7.9   5.1   127.5   147.8   112.2  
SU-DHL-6   4.6   4.9   17.3   11.0   1199.3   1308.9   572.3  
FSCCL
 
2.7
 
2.7
 
8.7
 
4.2
 
8.9
 
12.5
 
466.8
 


Geometric mean fluorescence

None
Anti-CEA: hMN14
Anti-CD74: hLL1
Anti-CD22: hLL2
Anti-CD20: hA20
Anti-CD20: rituximab
Anti-HLA-DR: hL243γ4P
Daudi   3.2   3.2   48.8   51.7   241.0   380.5   937.4  
Namalwa   2.6   2.4   7.8   6.4   10.1   14.1   260.9  
Raji   6.9   7.0   95.1   22.6   267.1   394.6   972.0  
Ramos   3.1   3.1   23.3   14.6   203.7   375.0   277.6  
RL   2.4   2.8   7.9   5.1   127.5   147.8   112.2  
SU-DHL-6   4.6   4.9   17.3   11.0   1199.3   1308.9   572.3  
FSCCL
 
2.7
 
2.7
 
8.7
 
4.2
 
8.9
 
12.5
 
466.8
 

An indirect flow cytometry assay was performed using FITC-GAH Fc-specific second antibody staining

or Create an Account

Close Modal
Close Modal